Randomized Phase Ii Study Of Docetaxel (D) Plus Abiraterone Acetate (Aa) Versus D After Disease Progression To First-Line Aa In Metastatic Castration-Resistant Prostate Cancer (Mcrpc): Abido-Sogug Trial

Miguel Angel Climent Duran,Albert Font,Ignacio Duran,Javier Puente,Daniel Castellano,M Isabel Sáez,Maria Jose José Mendez Vidal,Carmen Santander,Jose Angel Arranz Arija,Aranzazu Gonzalez del Alba,Alfredo Sanchez-Hernandez,Emilio Esteban,Teresa Alonso Gordoa,Pablo Maroto,Martín Emilio Lázaro Quintela,Javier Cassinello,Begona Perez Valderrama,María José Juan Fita,Begona Mellado

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 2|浏览82

暂无评分

摘要

95Background: Abiraterone acetate (AA) improves OS and rPFS in first line mCRPC patients (pts). After AA progression D is commonly used as standard second line therapy. However, the value of mainta...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要